News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-16 EDT			5-day change	1st Jan Change
37.00 ^USD	-2.17%		-0.19%	+20.13%

10-16	Nordic stocks in North America - Ericsson rose 2.6 percent	FW
10-15	Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug	RE

All News

Mentions Relevance

10-14	UBS Raises Genmab Price Target to DKK 3,100 (2,700), Reiterates Buy	FW
10-13	Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2026	CI
10-13	Genmab Reports $4.24 Billion in Q3 DARZALEX Sales, Earns Royalties From J&J	MT
10-13	Genmab: Darzalex sales reached $4.2bn in third quarter	FW
10-13	Genmab reports Darzalex sales of $4.24bn	FW
10-13	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026	GL
10-13	BNP Paribas raises its price target for Genmab to DKK 2,850 (2,600), reiterates outperform - BN	FW
10-09	BofA 'Bullish' on Genmab's Upcoming Phase 3 Readouts; Buy Rating Maintained	MT
10-09	Deutsche Bank raises price target for Genmab to 3,000 Danish kroner, reiterates buy	FW
10-09	Deutsche Bank raises price target for Genmab to DKK 3,000 (2,750), reiterates buy	FW
10-08	Barclays raises price target for Genmab to DKK 3,100 (2,900), reiterates overweight	FW
10-07	Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members	GL
10-07	Genmab: Beyond Darzalex
10-07	Deutsche Bank Research Raises Genmab PT, Keeps Buy Rating	MT
10-07	Deutsche Bank reiterates buy on Genmab, raises price target to DKK 2,750	FW
10-07	DNB Carnegie raises price target for Genmab to DKK 2,850 (2,300), reiterates buy	FW
10-06	Bank of America raises target price for Genmab to 2,850 Danish kroner (2,500), reiterates buy	FW
10-06	Deutsche Bank raises price target for Genmab to DKK 2,750 (2,500), reiterates buy	FW
10-06	Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug	DJ
10-06	Jefferies impressed by Genmab's results in a phase 3 study
10-06	SEB reiterates Buy on Genmab, raises price target to DKK 3,000 (Update)	FW
10-06	SEB raises its price target for Genmab to DKK 3,000 (2,600), reiterates buy	FW
10-06	Barclays: Genmab's Epkinly beats expectations	FW
10-05	Genmab, AbbVie Report Positive Results from Phase 3 Trial of Diffuse Large B-Cell Lymphoma Treatment	MT
10-05	Genmab A/S And AbbVie Announce Epcoritamab In Combination With R-CHOP Demonstrates Statistically Significant Improvement In Progression-Free Survival In Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI